In an 87‑year‑old patient who collapsed and presents to the emergency department with atrial fibrillation with rapid ventricular response, should digoxin or amiodarone be used for acute rate control?

Amiodarone is the preferred agent for acute rate control in this 87-year-old patient with atrial fibrillation with rapid ventricular response and hemodynamic instability (collapse).

In an elderly patient presenting with collapse and AF with RVR, intravenous amiodarone should be used for acute rate control rather than digoxin. The collapse suggests hemodynamic instability, which makes amiodarone the superior choice based on current guidelines and the clinical context.

Rationale for Amiodarone Over Digoxin

Hemodynamic Considerations

The patient's presentation with collapse indicates hemodynamic compromise. The 2025 AHA Advanced Life Support Guidelines specifically recommend intravenous amiodarone for rate control in critically ill patients or those with hemodynamic instability 1. The 2014 AHA/ACC/HRS guidelines similarly state that IV amiodarone can be useful for rate control in critically ill patients without pre-excitation (Class IIa, Level B) 2.

Digoxin's Critical Limitations in This Setting

Digoxin has three major disadvantages that make it inappropriate for this acute presentation:

1. Delayed onset of action: Digoxin requires at least 60 minutes before therapeutic effect begins, with peak effect not developing for up to 6 hours 3. In a patient who has collapsed, this delay is unacceptable.

2. Ineffective in high sympathetic states: The acute stress of collapse and ED presentation creates a high sympathetic tone state where digoxin efficacy is markedly reduced 3, 4. The 2025 AHA guidelines explicitly note that digoxin is less commonly used in the acute setting because of slow onset of effect 1.

3. Narrow therapeutic window in elderly: At 87 years old, this patient is at high risk for digoxin toxicity. The FDA label warns that low body weight, advanced age, and impaired renal function predispose to digoxin toxicity 5. Elderly patients frequently have reduced renal clearance, increasing toxicity risk.

Supporting Evidence for Amiodarone

Research demonstrates amiodarone's superiority in critically ill patients. A 1998 study showed that intravenous amiodarone (mean 242 mg over 1 hour) decreased heart rate by 37 beats/min while increasing systolic blood pressure by 24 mmHg in critically ill patients with atrial tachyarrhythmias refractory to conventional therapy 6. This hemodynamic profile—slowing rate while supporting blood pressure—is ideal for a patient presenting with collapse.

The 2016 ACC/AHA/HRS guidelines note that amiodarone may be useful for rate control in non-pre-excited atrial flutter/fibrillation because it produces less hypotension than beta blockers, diltiazem, and verapamil, making it preferred in critically ill patients or those with tenuous hemodynamic stability 7.

Practical Implementation

Amiodarone Dosing

• Loading dose: 150 mg IV over 10 minutes 7, 3
• Maintenance infusion: 0.5-1 mg/min IV 7
• Monitor for hypotension and bradycardia during infusion 1

Critical Exclusions

Do not use either agent if pre-excitation (WPW syndrome) is present. Both digoxin and IV amiodarone are contraindicated in AF with pre-excitation as they may paradoxically accelerate ventricular response and precipitate ventricular fibrillation 2, 5. In pre-excitation with hemodynamic instability, immediate electrical cardioversion is indicated 2.

Alternative First-Line Agents to Consider

If the patient is not critically ill or hemodynamically unstable (which seems unlikely given the collapse):

• IV diltiazem or IV metoprolol are actually preferred first-line agents for acute rate control in stable patients 1, 8
• A 2009 RCT showed IV diltiazem achieved rate control faster (median 3 hours) than either digoxin (6 hours) or amiodarone (7 hours) in acute AF 9

However, the 2025 AHA guidelines caution that nondihydropyridine calcium channel antagonists and beta-blockers can be harmful in decompensated patients 1. Given this patient collapsed, these agents carry higher risk.

Common Pitfalls

1. Assuming digoxin is appropriate for elderly patients: While digoxin is often used in older adults for chronic rate control, it is poorly suited for acute management, especially in the ED setting with hemodynamic compromise.

2. Overlooking heart failure status: If this patient has heart failure with reduced ejection fraction, amiodarone becomes even more appropriate as beta-blockers and calcium channel blockers may worsen hemodynamics 2. The 2014 AHA/ACC/HRS guidelines state that in the absence of pre-excitation, IV digoxin or amiodarone is recommended to control heart rate acutely in patients with HF (Class I, Level B) 2.

3. Not considering electrical cardioversion: If the patient remains hemodynamically unstable despite pharmacologic therapy, immediate electrical cardioversion is indicated 2. Pharmacologic rate control should not delay cardioversion in unstable patients.

Bottom Line Algorithm

For an 87-year-old with collapse and AF with RVR:

1. Assess hemodynamic stability and exclude pre-excitation on ECG
2. If hemodynamically unstable → immediate electrical cardioversion
3. If stable enough for pharmacologic therapy but critically ill → IV amiodarone (150 mg over 10 min, then 0.5-1 mg/min)
4. Avoid digoxin in the acute ED setting due to delayed onset
5. Monitor for conversion to sinus rhythm, as amiodarone may cardiovert the rhythm in addition to controlling rate 7

7, 1, 2, 5, 6